BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Intriguing Strange Cruising Objections you Should Visit - 2What's an atmospheric river? AP explains the weather phenomenon
- 3One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- 4Vote in favor of your Number one Sort of Cap
- 5SUVs Known for Their Looks As opposed to Their Capacity
- Language Learning Stages: Which One Gets Your Vote?
- Defense Minister Katz finally condemns Jewish extremist violence against Palestinians
- Poll: 62% of Americans would oppose U.S. military action in Greenland
- NASA begins the countdown for humanity's first launch to the moon in 53 years
- Building an Individual Brand: Illustrations from Forces to be reckoned with
- 'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- Indonesian Mega-Farm Drives Surge in Deforestation
- Where should we send a real 'Hail Mary' spacecraft? A new study has the answers
- Beneficial Growing Conditions in West Africa Weigh on Cocoa Prices
